Skip to Content

Tyvaso Side Effects

Generic Name: treprostinil

Note: This page contains side effects data for the generic drug treprostinil. It is possible that some of the dosage forms included below may not apply to the brand name Tyvaso.

In Summary

Common side effects of Tyvaso include: cough, headache, pharyngitis, flushing, and pharyngolaryngeal pain. Other side effects include: syncope. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to treprostinil: oral tablet extended release

As well as its needed effects, treprostinil (the active ingredient contained in Tyvaso) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking treprostinil, check with your doctor immediately:

More common:
  • Decreased urine
  • dry mouth
  • increased thirst
  • irregular heartbeat
  • muscle pain or cramps
  • nausea or vomiting
  • pain in the jaw, arms, or legs
  • unusual tiredness or weakness

If any of the following symptoms of overdose occur while taking treprostinil, get emergency help immediately:

Symptoms of overdose:
  • Blurred vision
  • confusion
  • diarrhea
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • headache, severe
  • sweating

Minor Side Effects

Some treprostinil side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Abdominal or stomach discomfort
  • diarrhea
  • feeling of warmth
  • headache
  • redness of the face, neck, arms, and occasionally, upper chest

For Healthcare Professionals

Applies to treprostinil: inhalation solution, injectable solution, oral tablet extended release


In general, the most common adverse effects have included infusion site pain and reactions.[Ref]


Local adverse effects have included infusion site pain (85%) and infusion site reactions (83%) such as erythema, induration, or rash. These effects were classified as severe in 39% and 38% of patients, respectively.[Ref]


Gastrointestinal side effects have included diarrhea (up to 30%), nausea (up to 30%), abdominal discomfort (6%), and vomiting.[Ref]

Nervous system

Nervous system side effects have included headache (up to 63%), dizziness (9%), and insomnia.[Ref]


Cardiovascular side effects have included vasodilatation (11%), edema (9%), hypotension (4%), bradycardia, syncope, and flushing. Postmarketing reports include angioedema.[Ref]


Dermatologic reactions have included rash (14%) and pruritus (8%). Postmarketing reports have included angioedema.[Ref]


Musculoskeletal side effects have included pain in extremity (14%), jaw pain (13%), and foot pain.[Ref]


Complications associated with infusion systems were related to the pump (93%) or to the infusion set (7%). Side effects were reported in 8 patients (4 treprostinil (the active ingredient contained in Tyvaso) and 4 placebo), including nausea (due to excess drug) and dyspnea (due to return of pulmonary arterial hypertension symptoms).

The following adverse events may be attributable to the IV mode of infusion including arm swelling, paresthesias, hematoma and pain. Using an indwelling central venous catheter to deliver chronic intravenous infusions of treprostinil is associated with the risk of blood stream infections and sepsis, which may be fatal.[Ref]

Other side effects include anorexia, vomiting, infusion site infection, asthenia, flushing (up to 15%), and abdominal pain.[Ref]


Respiratory side effects of inhaled treprostinil (the active ingredient contained in Tyvaso) have included cough, throat irritation, and pharyngolaryngeal pain.[Ref]


Common (1% to 10%): Hypokalemia (9%)


1. "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.

2. McLaughlin VV, Gaine SP, Barst RJ, et al. "Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension." J Cardiovasc Pharmacol 41 (2003): 293-9

3. "Product Information. Tyvaso (treprostinil)." United Therapeutics Corporation, Silver Spring, MD.

It is possible that some side effects of Tyvaso may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.